Coronary Vasomotor Response After Riociguat Exposure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-31

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to assess the effects of intracoronary Riociguat on coronary blood flow in subjects with coronary artery disease and to compare this effect with the intracoronary nitroglycerin, a coronary vasodilator widly used to treat patients with coronary artery disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance

NCT00733174

Impaired Glucose Tolerance

UNKNOWN PHASE4

Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator

NCT01926847

Raynaud Disease

COMPLETED PHASE2

Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease

NCT05762952

Myocardial Ischemia

RECRUITING PHASE1

Rosiglitazone Versus Placebo in Chronic Stable Angina

NCT00225355

Angina Pectoris Metabolic Syndrome X

TERMINATED PHASE4

Integrating Pharmacogenetics In Clinical Care

NCT02871934

Cardiovascular Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

Group Type EXPERIMENTAL

Riociguat (BAY63-2521)

Intervention Type DRUG

0.1 mg intracoronary infusion through coronary guide catheter. Single dose. Sequential application after initial vasoactive bolus of Adenosine (non-study drug) and Nitroglycerin (non-study drug).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Riociguat (BAY63-2521)

0.1 mg intracoronary infusion through coronary guide catheter. Single dose. Sequential application after initial vasoactive bolus of Adenosine (non-study drug) and Nitroglycerin (non-study drug).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients with coronary artery disease

Exclusion Criteria

* Patents with coronary artery disease with \>/= 70% luminal stenosis by coronary angiography in one of the 3 major epicardial coronary arteries (left anterior descending artery \[LAD\], left circumflex coronary artery \[LCX\] or right coronary artery \[RCA\]) undergoing cardiac catheterization

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No